Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4265MR)

This product GTTS-WQ4265MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4265MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4977MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ8675MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ301MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ11159MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ1898MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ11003MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ1245MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ4996MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA C4G1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW